<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7808616</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7840</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Neurosci.</journal-id>
<journal-title-group>
<journal-title>Trends in neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">0166-2236</issn>
<issn pub-type="epub">1878-108X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26830113</article-id>
<article-id pub-id-type="pmc">4924590</article-id>
<article-id pub-id-type="doi">10.1016/j.tins.2015.12.008</article-id>
<article-id pub-id-type="manuscript">NIHMS797145</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rett Syndrome: Crossing the Threshold to Clinical Translation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Katz</surname>
<given-names>David M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bird</surname>
<given-names>Adrian</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coenraads</surname>
<given-names>Monica</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gray</surname>
<given-names>Steven J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Menon</surname>
<given-names>Debashish U.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Philpot</surname>
<given-names>Benjamin D.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tarquinio</surname>
<given-names>Daniel C.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Departments of Neurosciences and Psychiatry, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA</aff>
<aff id="A2"><label>2</label>Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, UK</aff>
<aff id="A3"><label>3</label>Rett Syndrome Research Trust, 67 Under Cliff Road, Trumbull, CT 06611, USA</aff>
<aff id="A4"><label>4</label>Gene Therapy Center and Department of Ophthalmology, University of North Carolina, Chapel Hill, NC USA</aff>
<aff id="A5"><label>5</label>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA</aff>
<aff id="A6"><label>6</label>Department of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, UNC School of Medicine, Chapel Hill, NC 27599, USA</aff>
<aff id="A7"><label>7</label>Children's Healthcare of Atlanta, Emory University, 1605 Chantilly Drive NE, Atlanta, GA 30324, USA</aff>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence: <email>david.katz@case.edu</email> (D.M. Katz)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>39</volume>
<issue>2</issue>
<fpage>100</fpage>
<lpage>113</lpage>
<!--elocation-id from pubmed: 10.1016/j.tins.2015.12.008-->
<abstract>
<p id="P1">Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>